Arkansas Children’s Receives .7M Grant for Antifungal Therapy Study
Arkansas Children’s Research Institute is set to conduct a groundbreaking study on antifungal therapy for childhood fungal infections. The study, funded by a .7 million grant from the National Institutes of Health, aims to define the optimal duration of antifungal therapy for invasive fungal diseases, particularly candidemia, which is the most common invasive fungal disease in children.
Uncomplicated Candidemia in Children
The goal of the seven-year study is to determine if children with uncomplicated candidemia can stop treatment after seven days or if they need to continue it for the currently recommended 14 days. The research focuses on the benefits and consequences of shorter-term treatment and could lead to improved guidelines for patient care.
Collaborative Efforts
The study is a collaborative effort involving researchers from Arkansas Children’s Research Institute and Children’s Hospital of Philadelphia. The team will utilize the International Pediatric Fungal Network, a 55-site research consortium, to gather data. Dr. William Steinbach and Dr. Brian Fisher are the co-principal investigators leading the study.
